share_log

Avalo Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Goldman Jonathan

SEC announcement ·  Apr 3 16:10
Summary by Moomoo AI
Jonathan Goldman, a director and 10% owner of Avalo Therapeutics, Inc. [AVTX], filed an Initial Statement of Beneficial Ownership of Securities with the SEC on March 27, 2024. The Form 3 filing, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that no securities are beneficially owned by Goldman. The form was signed by Donald R. Reynolds by power of attorney on April 3, 2024. This filing is a standard procedure for directors and significant shareholders, providing transparency about their holdings in the company.
Jonathan Goldman, a director and 10% owner of Avalo Therapeutics, Inc. [AVTX], filed an Initial Statement of Beneficial Ownership of Securities with the SEC on March 27, 2024. The Form 3 filing, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that no securities are beneficially owned by Goldman. The form was signed by Donald R. Reynolds by power of attorney on April 3, 2024. This filing is a standard procedure for directors and significant shareholders, providing transparency about their holdings in the company.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more